# Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

> **NCT02649751** · PHASE2 · TERMINATED · sponsor: **University Hospital, Brest** · enrollment: 49 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Roscovitine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02649751
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-22
- **Primary completion:** 2018-07-26
- **Final completion:** 2018-07-26
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** The centers have no longer patients. In September 2018, set up of a competitive international study.
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649751, "Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02649751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*